Over the first ten months of 2025, Russian consumers purchased almost 19.1 million packs of antidepressants on the retail pharmaceutical market, totaling more than 15.7 billion rubles (in retail prices, including VAT). According to the “Retail Sales Audit of Medicinal Products in Russia (total sell out)” database by the analytical company RNC Pharma, the physical consumption of the analyzed medicines increased by 24 percent, while consumer spending exceeded the figures for the same period of the previous year by 36 percent. For the third consecutive year, sales volumes of these products have been growing at double-digit rates. In total, over the whole of 2024, the retail physical volume of sales was lower than the ten-month result of the current year: consumers purchased around 19 million packs of antidepressants for 14.4 billion rubles.

Throughout the year, demand for antidepressants (group N06A) does not demonstrate sharp declines, while sales volumes typically rise in spring and autumn. In the current year, the highest demand was recorded in October — during this month, 2.2 million packs were purchased for 1.84 billion rubles, which is 36.7 percent higher than consumer spending on these medicines in October 2024, while physical consumption increased by 24.8 percent over this period. It is noteworthy that demand remained high even in the summer months: in July and August, monthly spending in this category exceeded 1.63 billion rubles.

A significant share of antidepressant consumption is concentrated in Moscow and the Moscow Region — based on the results of the first ten months of 2025, these regions accounted for almost 31 percent of the entire retail market in value terms. At the same time, the dynamics of value sales here were lower than the national average: at +28 percent and +33 percent respectively. The highest growth rates in consumption this year were recorded in Kamchatka Krai (+55 percent in value) and Vologda Region (+54 percent).

Over the first ten months of 2025, the retail market featured 88 brands from 55 companies. Almost 18 percent of spending in this group was generated by products of the Danish company H. Lundbeck; the absolute category leader is Cipralex, and the company is represented by three brands in total. The Slovenian company KRKA rose from fourth to second place in the ranking. In Russia, the company offers four products; the key one is Duloxenta (INN duloxetine), which served as the primary growth driver — consumer spending on this brand increased by 79 percent year-on-year. Abbott moved down to third place with a market share of 11.6 percent; nevertheless, the company’s leading brands also demonstrated strong growth: sales of Fevarin (INN fluvoxamine) increased by 27 percent in value over the year, and sales of Selectra (INN escitalopram) by 44 percent.

It should be noted that all companies in the top ten demonstrated double-digit value growth during the reporting period. The strongest performance was recorded for Viatris — over the year, sales of Zoloft (INN sertraline) rose by 60 percent, with physical consumption up by 50 percent. Another notable example in this group is the Russian company Canonpharma. Compared with January–October of the previous year, sales of the manufacturer’s products increased by more than half, while physical demand rose by 40 percent.

Fig. Monthly consumption of antidepressants (group N06A — according to the EphMRA classification) in Russia, January 2024–October 2025, billion rubles (in retail prices, including VAT)